Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06496607 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Solriktug in Adult Participants With Asthma
A Phase 2 study of Asthma, sponsored by Uniquity One (UNI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06496607: Recruiting Phase 2 study of Asthma, sponsored by Uniquity One (UNI).
NCT06496607 is a Phase 2 study of Asthma that is actively recruiting participants, run by Uniquity One (UNI). The registered enrollment target is 140 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06496607, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by Uniquity One (UNI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Primary Outcome
Change from baseline in blood eosinophil counts evaluated over Weeks 8 to 12
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NSI-8226
Study Locations (20)
California
- Warren W. Pleskow, M.D. - Encinitas
- Beach Physicians Clinical Research Corp. - Huntington Beach
- Biosolutions Clinical Research Center - La Mesa
- Orso Health - Long Beach
- Downtown LA Research Center - Los Angeles
- Newport Native MD, Inc. - Newport Beach
- Prospective Research Innovations Inc. - Rancho Cucamonga
- Allergy & Asthma Medical Group and Research Center - San Diego
- Allergy & Asthma Associates of Santa Clara Valley - San Jose
- San Jose Clinical Trials - San Jose
- North Bay Clinical Research - Santa Rosa
- Providere Research - West Covina
Florida
- Clinical Research of West Florida - Clearwater
- JY Research Institute - Cutler Bay
- Hillcrest Medical Research, LLC - DeLand
- Clinical Site Partners LLC dba-Leesburg - Leesburg
- Pharmax Research of South Florida - Miami
Alabama
- Velocity Clinical Research - Mobile
Arizona
- Phoenix Medical Group - Peoria
Colorado
- Velocity Clinical Research - Denver - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-07-26 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What NCT06496607 shows while recruiting
NCT06496607 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06496607 names 20 study sites across 5 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06496607 about?
NCT06496607 is a clinical study titled "A Study to Evaluate Solriktug in Adult Participants With Asthma". Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
What is the current status of trial NCT06496607?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2024-07-26. Estimated completion is 2026-09-30.
What conditions does trial NCT06496607 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06496607?
The interventions under investigation include: Placebo (BIOLOGICAL), NSI-8226 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06496607?
This trial is sponsored by Uniquity One (UNI), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06496607 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06496607's enrollment target sits among peer trials
140 190th of 374 higher than 184 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI